Cyramza (ramucirumab) / Eli Lilly, Innovent Biologics  >>  Phase 2
Welcome,         Profile    Billing    Logout  

66 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cyramza (ramucirumab) / Eli Lilly
NCT04656002: As a Second-line Treatment for Metastatic Gastric Adenocarcinoma Patients, the Safety and Effective of Vactosertib Administration in Combination With Paclitaxel+Ramucirumab is Evaluated, and a Phase 2a Clinical Trial to Biomarkers

Not yet recruiting
2a
43
NA
Vactosertib, TEW-7197
Samsung Medical Center
Gastric Cancer
12/23
12/24
ACTRN12616001187437: Molecular Profiling and Matched Targeted Therapy for Patients with Metastatic Melanoma (MatchMel)

Not yet recruiting
2
1000
 
Melanoma Institute Australia, Melanoma Institute Australia, National Health and Medical Research Council
Metastatic Melanoma
 
 
OSIRAM-1, jRCT2080224085: A Randomized Phase II Study of Osimertinib + Ramucirumab Versus Osimertinib as First-Line Chemotherapy for EGFR Mutation-Positive Non-Squamous Cell Non-Small Cell Lung Cancer

Completed
2
120
Japan
Tagrisso (osimertinib) - AstraZeneca, Cyramza (ramucirumab) - Eli Lilly
Kanagawa Prefectural Cancer Center
EGFR mutation-positive non-squamous non-small-cell lung cancer
 
 
jRCTs041210105: Trifluridine/tipiracil (FTD/TPI) plus ramucirumab (Ram) for advanced gastric cancer

Active, not recruiting
2
32
Japan
Lonsurf (trifluridine/tipiracil) - Otsuka, Cyramza (ramucirumab) - Eli Lilly
Nagoya University Graduate School of Medicine
Gastric cancer
 
 
2014-003791-23: Clinical Trial Testing the Safety of Four Ramucirumab Doses Given as Second Line Treatment to Patients with Stomach Cancer

Ongoing
2
14
Europe
ramucirumab, Cyramza, Cyramza
Eli Lilly and Company, Eli Lilly and Company
Second Line Gastric or Gastroesophageal Junction Adenocarcinoma
 
 
2007-006713-16: Phase II Randomized, Open-Label Study of IMC-1121B With or Without Dacarbazine in Patients with Metastatic Malignant Melanoma

Ongoing
2
10
Europe
IMC-1121B, Dacarbazine, IMC-1121B,
ImClone Systems Incorporated
Metastatic Malignant Melanoma
 
 
NCT02711553 / 2015-004699-31: A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

Checkmark PFS data or from merestinib for advanced biliary tract cancer
Dec 2019 - Dec 2019: PFS data or from merestinib for advanced biliary tract cancer
Active, not recruiting
2
309
Europe, US, RoW
Ramucirumab, LY3009806, Merestinib, LY2801653, Cisplatin, Gemcitabine, LY188011, Placebo Oral, Placebo IV
Eli Lilly and Company
Biliary Tract Cancer, Metastatic Cancer, Advanced Cancer
02/18
12/25
2017-001683-37: SecOnd-line Chemotherapy with RAmucirumab +/- pacliTaxel in Elderly advanced gastric or gastroesophageal junction cancer patients SecOnde ligne de Chimiothérapie avec RAmucirumab +/- pacliTaxel chez le sujet âgE avec un cancer avancé de l’estomac ou de la jonction oeso-gastrique

Ongoing
2
112
Europe
Ramucirumab, Taxol, Concentrate for solution for infusion, Solution for infusion, Cyramza, Taxol
Fédération Francophone de Cancérologie Digestive, Lilly
Elederly patient with advanced gastric or gastroesophageal junction cancer, after first line chemotherapy patient âgé présentant un cancer avancé de l'estomac ou de la jonction oesogastrique, après une première ligne de chimiothérapie, Elederly patient with advanced gastric or gastroesophageal junction cancer, after first line chemotherapy patient âgé présentant un cancer avancé de l'estomac ou de la jonction oesogastrique, après une première ligne de chimiothérapie, Diseases [C] - Cancer [C04]
 
 
2017-004494-13: IMPROVING TREATMENT STRATEGIES IN THYMIC EPITHELIAL TUMORS: A TYME COLLABORATIVE EFFORT Miglioramento delle strategie di trattamento nei tumori epiteliali del timo: un impegno congiunto del TYME.

Ongoing
2
60
Europe
Cyramza, [IMP1], Concentrate for solution for infusion, CYRAMZA - 10 MG/ML- CONCENTRATO PER SOLUZIONE PER INFUSIONE- USO ENDOVENOSO- FLACONCINO (VETRO) 50 ML- 1 FLACONCINO
FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI", AIFA - Italian Medicines Agency
Patients diagnosed with thymic carcinoma / thymoma B3 with areas of carcinoma with metastatic or relapsed non-pre-treated disease. Pazienti con diagnosi di carcinoma timico/ timoma B3 con aree di carcinoma con malattia metastatica o recidivata non pretrattati., thymic carcinoma carcinoma timico, Diseases [C] - Cancer [C04]
 
 
2017-001207-68: A study to investigate the efficacy of ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic neuroendocrine tumors of the pancreas Studie zur Untersuchung der Wirksamkeit von Ramucirumab in Kombination mit Dacarbazin bei Patienten mit neuroendokrinen, fortgeschrittenen Tumoren der Bauchspeicheldrüse, welche eventuell schon Absiedlungen (Metastasen) gebildet haben.

Ongoing
2
45
Europe
Concentrate for solution for infusion, Cyramza 10 mg/ml
Martin-Luther-Universität Halle-Wittenberg, Lilly Deutschland GmbH
Progressive well-differentiated metastatic pancreatic neuroendocrine tumors Progrediente, gut differenzierte metastasierte pankreatische neuroendokrine Tumore, Progressive well-differentiated metastatic neuroendocrine tumors of the pancreas Neuroendokriner Tumor der Bauchspeicheldrüse, welcher fortgeschritten ist und eventuell schon Absiedlungen (Metastasen) gebildet hat, Diseases [C] - Cancer [C04]
 
 
RamAtezo-1, NCT03689855: Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC

Completed
2
21
US
Ramucirumab, Cyramza, Atezolizumab, Tecentriq, Peripheral blood draw, Biopsy
Washington University School of Medicine, Eli Lilly and Company
Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, NSCLC
07/21
04/24
RELEVENT, NCT03921671 / 2017-004494-13: Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma

Active, not recruiting
2
60
Europe
Ramucirumab, CARBOPLATIN (AUC 5) + PACLITAXEL(200 mg / m2)
Claudia Proto, AIFA - Italian Medicines Agency
Thymic Carcinoma, Thymoma
10/21
07/24
NCT03686488: TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Active, not recruiting
2
23
US
TAS 102, Lonsurf, Ramucirumab 10 MG/ML Intravenous Solution [CYRAMZA]
H. Lee Moffitt Cancer Center and Research Institute
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Gastric Cancer
01/22
07/24
Lung-MAP Non-Matched Sub-Study, NCT03971474: Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

Active, not recruiting
2
166
US
Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Gemcitabine Hydrochloride, Difluorodeoxycytidine Hydrochloride, Gemzar, LY-188011, LY188011, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Pemetrexed, MTA, Multitargeted Antifolate, Pemetrexed Disodium, Alimta, LY231514, N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt, Ramucirumab, anti-VEGFR-2 fully human monoclonal antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806, Monoclonal Antibody HGS-ETR2
SWOG Cancer Research Network, National Cancer Institute (NCI)
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
04/22
07/24
EAST ENERGY, NCT04040361: Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer

Recruiting
2
24
Japan
Pembrolizumab, MK3475, Ramucirumab, LY3009806, Surgery
Masahiro Tsuboi, Merck Sharp & Dohme LLC, Eli Lilly and Company
Non-small Cell Lung Cancer Stage IB, Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage ⅢA
04/22
11/25
NCT03502746: Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma

Terminated
2
34
US
Nivolumab, Opdivo, Ramucirumab, Cyramza
Arkadiusz Z. Dudek, MD, HealthPartners Institute Regions Cancer Care Center, Eli Lilly and Company, Bristol-Myers Squibb
Mesothelioma, Malignant
05/22
11/23
2020-002512-49: An open-label study to investigate the efficacy of Cinrebafusp Alfa with Ramucirumab and Paclitaxel in patients with Adenocarcinoma, and Cinrebafusp Alfa with Tucatinib in Patients with Adenocarcinoma Estudio abierto de la eficacia de cinrebafusp alfa con ramucirumab y paclitaxel en pacientes con adenocarcinoma, y cinrebafusp alfa con tucatinib en pacientes con adenocarcinoma

Not yet recruiting
2
87
Europe
PRS-343, Ramucirumab, Tucatinib, Paclitaxel, Solution for infusion, Orodispersible tablet, Cyramza, TUKYSA, Paclitaxel
Pieris Pharmaceuticals, Inc., Pieris Pharmaceuticals, Inc.
HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Adenocarcinoma de la unión gástrica o gastroesofágica (UGE) HER2 positivo y adenocarcinoma de la unión gástrica o gastroesofágica (UGE) con expresión baja de HER2, HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Adenocarcinoma de la unión gástrica o gastroesofágica (UGE) HER2 positivo y adenocarcinoma de la unión gástrica o gastroesofágica (UGE) con expresión baja de HER2, Diseases [C] - Cancer [C04]
 
 
AIO-STO-0218, NCT03966118: Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma

Recruiting
2
59
Europe
Avelumab, Ramucirumab, Paclitaxel
P. C. Thuss-Patience
Gastroesophageal Junction Adenocarcinoma, Adenocarcinoma of the Stomach
09/22
09/23
2018-002938-20: Avelumab + Paclitaxel/ Ramucirumab als Zweitlinientherapie beim gastro-ösophagealen Adenokarzinom: eine Phase-II-Studie der AIO - RAP-Studie

Not yet recruiting
2
59
Europe
Concentrate for solution for infusion, , Bavencio, Cyramza
Charite - Universitätsmedizin Berlin, Merck KGaA
metastatic gastro-oesophageal cancer, Cancer of the stomach or lower gullet, Diseases [C] - Cancer [C04]
 
 
NCT04632459: Pembrolizumab Plus Ramucirumab in Metastatic Gastric Cancer

Recruiting
2
35
RoW
pembrolizumab plus ramucirumab
Samsung Medical Center
Gastric Cancer
12/22
12/22
NCT02581215: Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer

Active, not recruiting
2
84
US
mFOLFIRINOX, Ramucirumab, Cyramza, Placebo
Walid Shaib, MD, Eli Lilly and Company, Hoosier Cancer Research Network
Pancreatic Cancer
12/22
12/23
NCT02795858: A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors

Active, not recruiting
2
43
US
Ramucirumab, Cyramza, Somatostatin Analog, octreotide, lanreotide
Dana-Farber Cancer Institute, Eli Lilly and Company
Carcinoid Tumors
12/22
12/24
2020-001075-32: A pilot study of ramucirumab beyond progression plus TAS-102 in patients with advanced or metastatic adenocarcinoma of the stomach or the gastroesophageal junction, after treatment failure on a ramucirumab based therapy Eine Pilotstudie mit Ramucirumab über den Progress hinaus in Kombination mit TAS-102 bei Patienten mit fortgeschrittenem oder metastasiertemAdenokarzinom des Magens oder des ösophagogastralen Übergangs,nach Therapieversagen einer Ramucirumab-basierten Therapie

Not yet recruiting
2
20
Europe
Ramucirumab, TAS102, Concentrate for solution for infusion, Film-coated tablet, Cyramza® 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Lonsurf
Institut für Klinische Krebsforschung IKF GmbH, Lilly Deutschland GmbH
advanced or metastatic adenocarcinoma of the stomach or the gastroesophageal junction, advanced or metastatic adenocarcinoma of the stomach or the gastroesophageal junction, Diseases [C] - Cancer [C04]
 
 
NCT05190445: Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma

Active, not recruiting
2
80
US, RoW
Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel, Cinrebafusp alfa (PRS-343) in combination with tucatinib
Pieris Pharmaceuticals, Inc.
HER2-positive Gastric Cancer
02/23
02/23
NCT05045404: Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer

Withdrawn
2
36
NA
Poziotinib Hydrochloride, 1429757-68-5, HM781-36B, NOV-1201 Hydrochloride, NOV120101 Hydrochloride, Poziotinib HCl, POZIOTINIB HYDROCHLORIDE
M.D. Anderson Cancer Center
Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
02/23
02/23
CARMEN-GC01, NCT05071053 / 2021-001967-26: Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer

Hourglass Apr 2022 - Dec 2022 : Data from CARMEN-GC01 trial in combination with ramucirumab for advanced gastric or gastroesophageal junction
Active, not recruiting
2
34
Europe, Japan, RoW
Ramucirumab (CYRAMZA®), Tusamitamab ravtansine (SAR408701)
Sanofi
Adenocarcinoma Gastric, Gastrooesophageal Cancer
06/23
06/24
NCT03141034: Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma

Completed
2
40
US
Irinotecan, Camptosar®, CPT-11, Ramucirumab, Cyramza®, Blood for angiome profiling, Blood for cfDNA
Washington University School of Medicine, Eli Lilly and Company
Gastric Adenocarcinoma, Gastro-esophageal Junction Adenocarcinoma
04/23
04/23
NCT04120454: Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer

Active, not recruiting
2
6
US
Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Ramucirumab, anti-VEGFR-2 fully human monoclonal antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806, Monoclonal Antibody HGS-ETR2
Ohio State University Comprehensive Cancer Center
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
08/23
12/23
RAMOSE, NCT03909334: Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting
2
160
US
Osimertinib, Tagrisso, Ramucirumab, Cyramza
Xiuning Le, M.D. Anderson Cancer Center, Eli Lilly and Company
Non Small Cell Lung Cancer, EGFR Gene Mutation, Advanced Cancer, Metastatic Cancer
05/24
06/24
NCT05942573: Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma: an Open-label, Randomised Phase II Trial

Recruiting
2
107
RoW
Serplulimab+Paclitaxel+Apatinib, A:Drug:Serplulimab+paclitaxel+Apatinib, Paclitaxel±Ramucirumab, B:Drug:paclitaxel±Ramucirumab
Tianjin Medical University Cancer Institute and Hospital
Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)
10/23
12/24
SEQUEL, NCT04069273: Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma

Recruiting
2
58
US
Pembrolizumab Monotherapy, Keytruda, Ramucirumab, Cyramza, Paclitaxel, Taxol
Harry H Yoon, Merck Sharp & Dohme LLC, Mayo Clinic
Gastric Cancer, GastroEsophageal Cancer, Adenocarcinoma
06/25
12/25
SOCRATE, NCT03760822: Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients

Active, not recruiting
2
112
Europe
Ramucirumab, Cyramza, Paclitaxel, Abraxane
Federation Francophone de Cancerologie Digestive, Eli Lilly and Company
Stomach Cancer, Stomach Neoplasm, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
12/23
09/24
NCT06251973: A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Recruiting
2
38
US
AgenT-797, Botensilimab, Balstilimab, Ramucirumab, Paclitaxel
Memorial Sloan Kettering Cancer Center
Metastatic Esophageal Carcinoma, Advanced Unresectable Gastric Adenocarcinoma, Metastatic Gastric Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Esophageal Cancer, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastric Carcinoma, Unresectable Esophageal Cancer, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Carcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
08/27
08/27
nextHERIZON, NCT05311176: A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer

Active, not recruiting
2
7
RoW
IMU-131, HER-Vaxx, Ramucirumab plus Paclitaxel, Standard of Care Chemotherapy, Pembrolizumab, Keytruda
Imugene Limited
Gastric Cancer, Cancer of Stomach, Gastric Adenocarcinoma, Stomach Cancer, Stomach Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
03/24
07/26
NCT03527108: Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC

Recruiting
2
39
US
Nivolumab, Ramucirumab
Fox Chase Cancer Center, Bristol-Myers Squibb, Eli Lilly and Company
Non Small Cell Lung Cancer
04/25
04/26
S1701, NCT03694002: Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery

Active, not recruiting
2
66
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806, Monoclonal Antibody HGS-ETR2
SWOG Cancer Research Network, National Cancer Institute (NCI)
Locally Advanced Thymic Carcinoma, Metastatic Thymic Carcinoma, Recurrent Thymic Carcinoma, Unresectable Thymic Carcinoma
06/24
11/24
NCT04310007: Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

Active, not recruiting
2
117
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Docetaxel, Docecad, RP 56976, RP56976, Taxotere, Taxotere Injection Concentrate, Echocardiography, EC, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Paclitaxel Nanoparticle Albumin-bound, Paclitaxel Protein-Bound, Protein-bound Paclitaxel, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806, Monoclonal Antibody HGS-ETR2
National Cancer Institute (NCI)
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
09/24
09/24
NCT06441019: Efficacy and Safety of HAIC in Combination With TQB2868 and Ramucirumab for Second-line Treatment of Advanced Hepatocellular Carcinoma

Not yet recruiting
2
42
RoW
HAIC（Oxaliplatin+ Raltitrexed）、TQB2868、Ramucirumab
Fudan University
Hepatocellular Carcinoma，Bispecific Antibodies, HAIC, Ramucirumab
05/25
05/26
NCT04660760: Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer

Recruiting
2
116
US
Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Quality-of-Life Assessment, Quality of Life Assessment, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806, Monoclonal Antibody HGS-ETR2, Trifluridine and Tipiracil Hydrochloride, Lonsurf, TAS 102, TAS-102, Tipiracil Hydrochloride Mixture with Trifluridine, Trifluridine/Tipiracil, Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102
Academic and Community Cancer Research United, National Cancer Institute (NCI)
Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Unresectable Gastric Adenocarcinoma, Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Pathologic Stage III Gastric Cancer AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastric Cancer AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastric Cancer AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIC Gastric Cancer AJCC v8, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
07/24
05/26
CARMEN-LC04, NCT04394624 / 2019-003914-15: Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC

Hourglass Apr 2022 - Dec 2021 : Data from CARMEN-LC04 trial in combination with ramucirumab for NSCLC
Active, not recruiting
2
31
Europe, US, RoW
SAR408701, ramucirumab, pembrolizumab
Sanofi
Non-small Cell Lung Cancer Metastatic
03/23
09/24
PLATFORM, NCT02678182: Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial

Recruiting
2
924
Europe
Capecitabine, MEDI4736, Trastuzumab, Rucaparib, Ramucirumab
Royal Marsden NHS Foundation Trust, MedImmune LLC, Clovis Oncology, Inc., Eli Lilly and Company, AstraZeneca
Adenocarcinoma of the Oesophagus, Adenocarcinoma of the Gastro-oesophageal Junction, Adenocarcinoma of the Stomach
03/25
06/27
NCT04332367: Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance

Recruiting
2
59
US
Carboplatin, Paraplatin, Paclitaxel, Abraxane, Taxol, Ramucirumab, Cyramza
Abramson Cancer Center at Penn Medicine
Non-small Cell Lung Cancer
04/25
04/25
SWOG S1922, NCT04205968: Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

Recruiting
2
94
US
Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Irinotecan, Irinotecan Hydrochloride, Campto, Camptosar, Camptothecin 11, Camptothecin-11, CPT 11, CPT-11, Irinomedac, Irinotecan Hydrochloride Trihydrate, Irinotecan Monohydrochloride Trihydrate, U-101440E, Leucovorin, Folinic acid, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806, Monoclonal Antibody HGS-ETR2
SWOG Cancer Research Network, National Cancer Institute (NCI)
Metastatic Small Intestinal Adenocarcinoma, Stage III Small Intestinal Adenocarcinoma AJCC v8, Stage IIIA Small Intestinal Adenocarcinoma AJCC v8, Stage IIIB Small Intestinal Adenocarcinoma AJCC v8, Stage IV Small Intestinal Adenocarcinoma AJCC v8
06/25
06/25
TaxRamPem, NCT04340882: Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade

Recruiting
2
41
US
Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806, Monoclonal Antibody HGS-ETR2
Emory University, National Cancer Institute (NCI), Merck Sharp & Dohme LLC
Metastatic Non-Small Lung Cell Cancer, Recurrent Non-Small Lung Cell Cancer, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
06/25
12/30
NCT06038578: A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

Recruiting
2
146
Japan, US, RoW
TRK-950, Ramucirumab, CYRAMZA®, Paclitaxel
Toray Industries, Inc
Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
08/25
08/25
NCT06043427: Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma

Recruiting
2
168
Canada
Paclitaxel, Ramucirumab, Zanidatamab
Canadian Cancer Trials Group, Jazz Pharmaceuticals
Gastroesophageal Adenocarcinoma
12/25
06/26
NCT06029127: A Study of BGB-A445 in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer

Recruiting
2
100
RoW
BGB-A445, Docetaxel, Ramucirumab, BGB-15025
BeiGene
Non-Small Cell Lung Cancer
01/26
05/26
CAMPFIRE, NCT05999994: A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

Recruiting
2
105
Europe, Japan, US, RoW
Ramucirumab, LY3009806, Cyclophosphamide, Vinorelbine, Gemcitabine, LY188011, Docetaxel, Abemaciclib, LY2835219, Irinotecan, Temozolomide
Eli Lilly and Company
Neoplasms, Child, Adolescent
05/26
05/26
Lung-MAP Sub-Study, NCT05642572: Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Recruiting
2
66
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Capmatinib, INC-280, INC280, INCB 28060, INCB028060, INCB28060, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Osimertinib, AZD-9291, AZD9291, Mereletinib, Tagrisso, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806, Monoclonal Antibody HGS-ETR2
SWOG Cancer Research Network, National Cancer Institute (NCI)
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
05/26
05/27
Rambro2, NCT05980000: Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma

Recruiting
2
72
US
Ramucirumab, Cyramza, Pembrolizumab, MK-3475, Keytruda
Washington University School of Medicine, Eli Lilly and Company
Recurrent Head and Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Metastatic Head and Neck Cancer, HNSCC
04/28
04/31
LUNG-MAP SUB-STUDY, NCT06031688: Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Not yet recruiting
2
56
NA
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Lymphoscintigraphy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806, Monoclonal Antibody HGS-ETR2, Tepotinib, c-Met Inhibitor MSC2156119J, EMD 1214063, EMD-1214063, EMD1214063, MSC2156119J
SWOG Cancer Research Network, National Cancer Institute (NCI)
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
05/28
05/29
2018-004283-65: A clinical study evaluating nivolumab-containing treatments in patients with advanced non-small cell lung cancer after failing previous PD-[L]1 therapy and chemotherapy

Not yet recruiting
1/2
550
Europe
NIVOLUMAB - 10mL vial- COMMERCIAL, Ipilimumab, Cabozantinib, Lucitanib, Docetaxel, BMS-936558, BMS-734016, XL184, CO-3810, Concentrate for solution for infusion, Film-coated tablet, Tablet, Opdivo (100 mg/10 mL), Cyramza 10 mg/ml concentrate for solution for infusion, Docetaxel Ebewe 10 mg/ml concentrate for solution for infusion, Doce NC® 10 mg/ml concentrate for solution for infusion
Bristol-Myers Squibb International Corporation, Bristol-Myers Squibb International Corporation
Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) after Failure of Platinum- Based Chemotherapy and Anti-PD-1 (L1) Immunotherapy, Non-small cell lung cancer that has spread or has reoccurred after failure of chemotherapy and immunotherapy, Diseases [C] - Cancer [C04]
 
 
HER-RAM, NCT04888663: Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer ( Study)

Active, not recruiting
1/2
50
RoW
Trastuzumab + Ramucirumab + Paclitaxel
Yonsei University
Recurrent/Metastatic Gastric Cancer
09/21
09/21
RACING, NCT03745430 / 2017-004792-30: RAmucirumab Combined wIth Standard Nab-paclitaxel and Gemcitabine as First-line Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma

Completed
1/2
54
Europe
Ramucirumab, Cyramza
Hellenic Cooperative Oncology Group, Eli Lilly and Company, Celgene Corporation
Pancreatic Adenocarcinoma
06/22
04/23
RiME, NCT03995017: Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma

Active, not recruiting
1/2
34
US
Rucaparib, Rubraca, Ramucirumab, Cyramza, Nivolumab, Opdivo, Bristol- Meyers Squibb (BMS)-936558
University of Kansas Medical Center, Bristol-Myers Squibb, Clovis Oncology, Inc.
Esophagus Cancer, Adenocarcinoma, Stomach Cancer, Adenocarcinoma
10/22
12/24
2019-004505-27: A Phase 1b/2 study of derazantinib as monotherapy and combination therapy with paclitaxel, ramucirumab or atezolizumab in patients with HER2-negative gastric adenocarcinoma harboring FGFR genetic aberrations (FIDES-03)

Not yet recruiting
1/2
314
Europe
Derazantinib, Paclitaxel EVER Pharma 6 mg/ml, Cyramza 100 mg/10ml, Tecentriq 1,200 mg, Cyramza 500 mg/50ml, [Ramucirumab], [Atezolizumab], [Paclitaxel], [Derazantinib], Capsule, hard, , Concentrate for solution for infusion, Paclitaxel EVER Pharma 6 mg/ml, Cyramza 100 mg/10ml, Tecentriq 1,200 mg, Cyramza 500 mg/50ml
Basilea Pharmaceutica International Ltd., Basilea Pharmaceutica International Ltd., Allschwil, Basilea Pharmaceutica International Ltd, Allschwil, Basilea Pharmaceutica International AG, Basilea Pharmaceutica International Ltd.
HER2-negative gastric adenocarcinoma harboring FGFR genetic aberrations, Stomach cancer, Diseases [C] - Cancer [C04]
 
 
NCT04145349 / 2018-004242-42: CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor

Active, not recruiting
1/2
34
Europe, Japan, US, RoW
Ramucirumab, LY3009806, Cyclophosphamide, Vinorelbine
Eli Lilly and Company
Desmoplastic Small Round Cell Tumor
06/24
10/24
NCT03650764: Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Hourglass Oct 2020 - Dec 2020 : From P1b trial in combination with Keytruda for metastatic HNSCC
Active, not recruiting
1/2
43
US
Ramucirumab, Cyramza, Pembrolizumab, Keytruda, EORTC QLQ-30, FACT H&N, Peripheral blood
Washington University School of Medicine, Eli Lilly and Company
Head and Neck Squamous Cell Carcinoma
12/24
12/24
NCT04921904: Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca

Not yet recruiting
1/2
30
US
Abemaciclib, Ramucirumab
Baylor Research Institute
Metastatic Esophageal Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma
06/24
06/24
NCT03008278: Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

Active, not recruiting
1/2
49
US
Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806, Monoclonal Antibody HGS-ETR2
National Cancer Institute (NCI)
Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma, Stage III Esophageal Cancer AJCC v7, Stage III Gastric Cancer AJCC v7, Stage IV Esophageal Cancer AJCC v7, Stage IV Gastric Cancer AJCC v7, Unresectable Esophageal Carcinoma, Unresectable Gastric Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
06/24
06/24
Keymaker-U06, NCT06445972: Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/)

Not yet recruiting
1/2
90
NA
Ramucirumab, Paclitaxel, MK-2870, SKB264, sacituzumab tirumotecan, sac-TMT
Merck Sharp & Dohme LLC
Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
12/26
10/28
MORPHEUS-EC, NCT03281369 / 2016-004529-17: A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Active, not recruiting
1/2
410
Europe, US, RoW
5-Fluorouracil (5-FU), Leucovorin, Folinic acid, Oxaliplatin, Atezolizumab, Tecentriq, Cobimetinib, Cotellic, Ramucirumab, Paclitaxel, PEGylated recombinant human hyaluronidase (PEGPH20), BL-8040, Linagliptin, Cisplatin, Tiragolumab, RO7092284
Hoffmann-La Roche, Halozyme Therapeutics, BioLineRx, Ltd.
Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
08/24
04/25
NCT05894824: An Open Label, Single-arm, Multicenter Phase Ib/II Study to Evaluate the Safety and Efficacy of T-Dxd in Combination With Ramucirumab as a 2nd Line in Patients With HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Not yet recruiting
1/2
46
NA
T-Dxd(Trastuzmab deruxtecan), Ramucirumab
Yonsei University
Gastric Cancer, Gastroesophageal Junction (GEJ) Cancer
05/25
01/26
NCT05927857: Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .

Not yet recruiting
1/2
45
NA
nal-IRI /Experimental, ONIVYDE, Ramucirumab /Experimental, Cyramza, Trifluridine/Tipiracil /Experimental, LONSURF
National Health Research Institutes, Taiwan, Taipei Veterans General Hospital, Taiwan, China Medical University Hospital, National Cheng-Kung University Hospital, Kaohsiung Medical University Chung-Ho Memorial Hospital, Chang Gung Memorial Hospital
Metastatic Gastric Adenocarcinoma, Second Line, Chemotherapy
08/25
12/25
Acclaim-2, NCT05062980: Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer

Recruiting
1/2
180
US
quaratusugene ozeplasmid, Reqorsa, pembrolizumab, Keytruda, docetaxel, Taxotere, ramucirumab, Cyramza, Investigator's Treatment of Choice
Genprex, Inc.
Non Small Cell Lung Cancer
11/27
11/28
NCT06007937: A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

Recruiting
1/2
56
US
Lorlatinib, Ramucirumab
Memorial Sloan Kettering Cancer Center, Eli Lilly and Company
Non Small Cell Lung Cancer, Metastatic, Recurrent
08/28
08/28

Download Options